Evidence supporting the use of: Vitamin B3 (various)
For the health condition: Arteriosclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Vitamin B3, also known as niacin, has scientific validation for its use in the management of arteriosclerosis, primarily due to its lipid-modifying effects. Niacin has been shown in multiple studies to significantly increase high-density lipoprotein (HDL) cholesterol and lower low-density lipoprotein (LDL) cholesterol and triglycerides. This lipid profile improvement is relevant because abnormal cholesterol and triglyceride levels are significant risk factors for arteriosclerosis, a condition characterized by the thickening and hardening of arterial walls due to plaque buildup.

Several randomized controlled trials, such as the Coronary Drug Project and the AIM-HIGH trial, have evaluated niacin’s effects on cardiovascular outcomes. While earlier studies suggested that niacin therapy could reduce cardiovascular events, more recent trials have not consistently shown a reduction in major cardiovascular outcomes when niacin is added to statin therapy. However, the ability of niacin to favorably modify lipid parameters is well established.

The evidence rating of 3 reflects that while niacin is effective at improving lipid profiles associated with arteriosclerosis risk, its impact on actual cardiovascular event reduction is less certain, particularly with modern therapies. Nevertheless, its use remains scientifically grounded, especially in cases where patients cannot tolerate statins or need additional lipid-lowering effects. Niacin is not generally used as monotherapy or first-line therapy for arteriosclerosis, but it is scientifically validated as an adjunct in selected cases.

More about Vitamin B3 (various)
More about Arteriosclerosis

Products containing Vitamin B3 (various)

We currently have no products on Vitabase that contain this ingredient.